Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation

Frazier, O.H.; Rose, Eric A.; Öz, Mehmet C.; Dembitsky, Walter P.; McCarthy, Patrick M.; Radovančević, Branislav; Poirier, Victor L.; Dasse, Kurt A.

doi:10.1067/mtc.2001.118274

Cited by 498 publications

(164 citation statements)

References 21 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…A prospective trial was designed to investigate this necessary comparison [22]. Twenty-four centers throughout the United States enrolled 280 transplant candidates who had been unresponsive to inotropic support with or without intra-aortic balloon counterpulsation.…”

Section: Ventricular Assist Devices In Clinical Usementioning

confidence: 99%

Ventricular Assist Devices as a Bridge to Transplant or Recovery

Kherani

Maybaum²,

Öz³

2004

Cardiology

Self Cite

View full text Add to dashboard Cite

Ventricular assist devices have emerged as the standard of care in treating end-stage heart failure. Their success in bridging patients to transplantation is well documented. The data supporting their ability to bridge patients to recovery is sparser. However, as technology continues to advance, these devices will offer a high quality of life both in and out of the hospital setting, making them options for a broader spectrum of heart failure patients.

show abstract

Section: Ventricular Assist Devices In Clinical Usementioning

confidence: 99%

Ventricular Assist Devices as a Bridge to Transplant or Recovery

Kherani

Maybaum²,

Öz³

2004

Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Second, pulsatile LVADs employed the use of a volume displacement chamber, resulting in a relatively large device. In turn, this required both a patient with a large body habitus and extensive dissection to accommodate implantation [10,11]. Third, owing to the mechanism of the volume displacement chamber, these pumps were often noisy.…”

Section: Introductionmentioning

confidence: 99%

Physiologic effects of continuous-flow left ventricular assist devices

Healy

McKellar

Drakos

et al. 2016

Journal of Surgical Research

View full text Add to dashboard Cite

Background Within the past ten years, continuous-flow Left Ventricular Assist Devices (LVADS) have replaced pulsatile-flow LVADs as the standard of care for both destination therapy and bridging patients to heart transplantation. Despite the rapid clinical adoption of continuous-flow LVADs, an understanding of the effects of continuous-flow physiology, as opposed to more natural pulsatile-flow physiology, is still evolving. Materials and Methods A thorough review of the relevant scientific literature regarding the physiologic and clinical effects of continuous-flow physiology was performed. These effects were analyzed on an organ system basis and include an evaluation of the cardiovascular, respiratory, hematologic, gastrointestinal, renal, hepatic, neurologic, immunologic, and endocrine systems. Results Continuous-flow physiology is, generally speaking, well tolerated over the long term. Several changes are manifest at the organ system level, however. While many of these changes are without appreciable clinical significance, other changes, such as an increased rate of gastrointestinal bleeding, appear to be associated with continuous-flow physiology. Conclusions Continuous-flow LVADs confer a significant advantage over their pulsatile-flow counterparts with regard to size and durability. From a physiologic standpoint, continuous-flow physiology has limited clinical effects at the organ system level. Though improved over previous generations, challenges with this technology remain. Approaching these problems with a combination of clinical and engineering solutions may be needed to achieve continued progression in the field of durable mechanical circulatory support.

show abstract

“…Potentially, the use of a VAD could be associated with acute organ failure [6]. Interaction mechanisms between VAD and internal organs have been hypothesized [7,8,9,10].…”

Section: Introductionmentioning

confidence: 99%

Effect of Percutaneous Ventricular Assist Devices on Renal Function

Mao¹,

Giuliani²,

Blanca-Martos³

et al. 2013

Blood Purif

View full text Add to dashboard Cite

Ventricular assist devices (VADs) are used to improve the systemic circulation and to decrease ventricular loading in patients with hemodynamic instability that is refractory to pharmacologic therapies. During an acute critical event, percutaneous devices are preferred because of their rapid deployment, since implantable devices require more extensive procedures. Implantable devices are used for patients with established end-stage heart failure as a bridge to heart transplantation, recovery or destination therapy. This report reviews mechanical principles and clinical studies regarding percutaneous VAD to address their potential renal effects. Since the focus of this study is set on devices that are dedicated to cardiac support only, extracorporeal membrane oxygenation systems are not included.

show abstract

Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation

Cited by 498 publications

References 21 publications

Ventricular Assist Devices as a Bridge to Transplant or Recovery

Ventricular Assist Devices as a Bridge to Transplant or Recovery

Physiologic effects of continuous-flow left ventricular assist devices

Effect of Percutaneous Ventricular Assist Devices on Renal Function

Contact Info

Product

Resources

About